Anti B-Cell 2-specific Antibody for the treatment of chronic Lymphocytic Leukaemia
ABC2ALL consortium will develop a novel therapeutic strategy to treat B-cell chronic lymphocytic leukemia (CLL). The consortium will design, produce and validate a therapeutic bispecific monoclonal antibody (mAb) that simultaneously targets two specific receptors expressed on malignant B-cells. This will provide improved efficacy, specificity, and safety when compared to the current treatment regimens. Upon completion of the project, the product will be ready for further clinical development.
2 641 060.00€
Pharmaceutical Products / Drugs
Other therapeutic (including defibrillators)